文献速递腹部MR

动脉期无强化的肝胆期低信号结节:消融或手术切除后是否存在肝细胞癌复发风险?系统评价与荟萃分析

Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2019-11-27

该系统评价与荟萃分析纳入8项研究共842例患者,评估治疗前钆塞酸增强MRI上动脉期无强化的肝胆期低信号结节对肝细胞癌患者肝内远处复发的风险。总体合并HR为2.44(95%CI 1.99-2.98),肝切除组HR为2.14(95%CI 1.66-2.76),射频消融组HR为3.07(95%CI 2.19-4.31),异质性I²=0%。结论认为这些结节是肝内远处复发的危险因素。

要点

  • 治疗前钆塞酸增强MRI上动脉期无强化的肝胆期低信号结节是肝细胞癌患者肝内远处复发的危险因素。
  • 总体合并HR为2.44(95%CI 1.99-2.98),异质性I²=0%。
  • 肝切除组HR为2.14(95%CI 1.66-2.76),射频消融组HR为3.07(95%CI 2.19-4.31)。

核心结论

  • 动脉期无强化的肝胆期低信号结节是接受射频消融或肝切除治疗的肝细胞癌患者肝内远处复发的危险因素。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed和EMBASE数据库至2019年4月6日,纳入8项研究共842例患者,采用随机效应模型合并 hazard ratio,使用QUIPS工具评估方法学质量。

诊断标准与关键数值

  • 总体合并肝内远处复发HR为2.44(95%CI 1.99-2.98)。
  • 肝切除患者肝内远处复发HR为2.14(95%CI 1.66-2.76)。
  • 射频消融患者肝内远处复发HR为3.07(95%CI 2.19-4.31)。
  • 其他亚组中这些结节作为肝内远处复发显著因素的HR范围为1.74-3.07。

临床应用与阅片要点

  • 作者认为,对于治疗前钆塞酸增强MRI上存在这些结节的肝细胞癌患者,可能需要对患者管理进行分层,考虑对这些结节进行额外检查或治疗,并修改适当的随访策略。

局限性

  • 纳入研究的方法学质量总体为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To perform a systematic review and meta-analysis to determine intrahepatic distant recurrence (IDR) risk of hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) on pretreatment gadoxetic acid-enhanced MRI in patients with hepatocellular carcinoma (HCC) treated with either hepatectomy or radiofrequency ablation (RFA).

METHODS: PubMed and EMBASE databases were searched up to April 6, 2019. We included studies that evaluated HBP hypointense nodules without APHE as risk factors for IDR in HCC patients treated with either hepatectomy or RFA. Hazard ratios (HR) were meta-analytically pooled using random effects model. Subgroup analyses stratified to clinicopathologic variables were performed to explore heterogeneity. Methodological quality of included studies was assessed using Quality in Prognostic Studies (QUIPS) tool.

RESULTS: Eight studies with 842 patients were analyzed. The overall pooled HR for IDR was 2.44 (95% CI, 1.99-2.98) and were 2.14 (95% CI, 1.66-2.76) and 3.07 (95% CI, 2.19-4.31) for patients that underwent hepatectomy and RFA, respectively. No significant heterogeneity was present (I2 = 0%). The presence of these nodules was consistently shown to be significant factors for IDR in other subgroups (HR = 1.74-3.07). Study quality was generally moderate.

CONCLUSIONS: HBP hypointense nodules without APHE are risk factors for IDR in HCC patients treated with either RFA or hepatectomy. Stratification of patient management with regard to performing additional tests or treatment for these nodules and modification of proper follow-up strategies may be required in patients with HCC who have these nodules on pretreatment gadoxetic acid-enhanced MRI.

KEY POINTS: • HBP hypointense nodules without APHE constitute an entity that is unique in gadoxetic acid-enhanced MRI. • HBP hypointense nodules without APHE are risk factors for IDR in HCC patients treated with either RFA or hepatectomy. • Stratification of management and modification of proper follow-up strategies may be required in HCC patients who have these nodules on pretreatment gadoxetic acid-enhanced MRI.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim TH, Woo S, Han S, et al. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol. 2019. PMID: 31776747. doi:10.1007/s00330-019-06499-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。